General instructions

Thanks for your support to CanScreen5 project. This form is to collect quantitative data on cervical cancer screening in the country/regions you are reporting for. The quantitative data mainly focuses on the target population, screening test outcomes, further assessment outcomes, cancer staging and treatment. **Terms in bold and underlined among the text have a definition at the end of the corresponding page.** If you require assistance in filling any of the data forms, please contact us by email at canscreen5@iarc.fr

We would prefer to receive the programme annual screening data (inclusion of participants during a one year period, e.g. 01/01/2017 to 31/12/2017, which will be considered as index year 2017; alternatively, 01/04/2018 to 31/03/2019, which will be considered as index year 2018). Otherwise, you can submit the data for one round of screening that extends over a few years.

CanScreen5 will prefer to get the data stratified by 5-year age groups. However, this is not mandatory, and data without age stratification can also be submitted.

Please fill in the general information as below:

1.	**General information**	
1.1	Country:_____	
1.2	Reporting for: *(1. national programme; 2. **sub-national programme**; 3. a **pilot programme** only; 4. a **demonstration project** only; 5. a **research project** only; 6. other_____)* *(If you are reporting for the national programme, please go to Q1.3 directly)*	[ ]
1.2a	If you are not reporting for a national programme, please name of the geographic area(s) :_____ _____	
1.3	Source: *(1. directly from programme (managed by Health Ministry/Health Authority); 2. official report (published by programme or Health Ministry/Health Authority); 3. peer-reviewed publication; 4. other reports (published by NGO/academic institutions); 5. other_____)* *(Please provide link (if available) or email the document to canscreen5@iarc.fr):* _____	[ ]
1.4	The period of reporting? (From mm/yyyy to mm/yyyy): [ ][ ]/[ ][ ][ ][ ] to [ ][ ]/[ ][ ][ ][ ]	
1.5	What's the primary screening test that is used in **screening protocol** you are reporting for? *(1.VIA; 2. cytology; 3. HPV; 4. HPV and cytology (co-testing))* *If applicable, please provide the criteria to consider a case eligible for the triage test*_____ *Please provide the criteria to consider a case eligible for colposcopy based on the primary test or primary and triage test* _____ *(If you want to submit data for programmes that use different screening tests, please fill in different forms for each test)*	[ ]
1.6	What's the triage screening test that is used in **screening protocol** you are reporting for? *(1. none; 2. VIA; 3.HPV; 4. cytology; 5. genotyping; 6. genotyping and cytology;7.genotyping and VIA; 8. other _____; 9. unknown)*	[ ]
1.7	Are you reporting data stratified by age group? *(1. yes, this form is for 5-year age group; 2. yes, this form is for 10-year age group; 3. no age stratified data)*	[ ]

Sub-national programme: A screening programme implemented at sub-national level is sub-national programme. Sub-national level indicates any government entity below the national level, regardless of the political, financial and administrative design of the country (e.g. province, state, cantonal level, etc.).

Pilot programme: Pilot programme is a small-scale implementation of screening programme to assess feasibility, impact on health services, barriers and facilitators of participation, etc. The Ministry of Health/Health Authority is already committed to implement a screening programme and has a well-defined plan to scale up the programme based on the lessons learnt from the pilot. All the elements of screening programmes are fully functional in the area under consideration at the time of implementing the pilot.

Demonstration project: Demonstration project is defined as screening implemented by or in collaboration with the Ministry of Health/Health Authority on a small scale to address one or several implementation issues. There is no documented policy or a commitment to scale up.

Research Project: In a research project screening is conducted by an entity (usually an academic body) to address a specific research question. Sometimes it is difficult to differentiate between demonstration and research projects. A research project more focusing on implementation and with active involvement of the Ministry of Health/Health Authority should be considered as a demonstration project.

Screening protocol: The protocol is a detailed documented plan on how to deliver the screening activities. As a minimum, the screening protocol should include clear information on the eligible women, target age, screening test, examination intervals, further assessment, referral system, and quality assurance.

This section concerns the invitation and screening.

- **Column A: Screening interval (in months):** What's the screening interval as per the protocol?
- **Column B: Target population**: How many age-eligible women (obtained from official statistics, irrespective of the screening interval) are there?
- **Column C: Invitation**: How many women were invited during the reporting period? (**leave blank if there is no invitation**).
- **Column D: Participation**: How many women were screened of those invited during the reporting period? (**leave blank if there is no invitation**).
  As a note, women who received the invitation during the reporting period (e.g. from 1 Jan 2018 to 31 Dec 2018) and received the screening testing during the first 6 months of next time period (e.g. by 30 Jun 2019) should be included in the total screening of invited for the reporting period.
- **Column E: Screened**: How many women were screened in total during the reporting period, **irrespective of invitation**? This is applicable if there is no system of invitation or if women have been screened without being invited (opportunistic screening). Please note that the numbers in this column may be the same as the numbers in column D, if women were screened after invitation only.
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

2. Invitation and screening

Are women personally invited? [ ] *(1. yes; 2. no (keep the column C, D blank))*

Age group (years)	A	B	C	D	E
	Interval	Population	Invitation (if applicable)	Participation (if applicable)	Screened
	Screening interval (in months)	Nº of women in the target age	Nº of women invited during the reporting period	Nº of women screened among invited	Nº of women screened
Stratified by 5 yrs					
20-24					
25-29					
30-34					
35-39					
40-44					
45-49					
50-54					
55-59					
60-64					
65-69					
*Other					
Stratified by 10 yrs					
20-29					
30-39					
40-49					
50-59					
60-69					
*Other					
No age stratification					
All in target age					

Any other information related to invitation and screening: _____

Screening interval: The interval between two screening episodes (rounds), within a screening programme or in an opportunistic setting.
Target population: Total number of women eligible for screening (usually by age, but the screening programme may have additional criteria) obtained from official statistics residing in the catchment area of a screening programme (national or subnational) as defined by the screening policy.
Invitation: An individual invitation (by letter, email, SMS, phone calls, home visits, or other methods) to the eligible women in the eligible target population to participate in the screening programme is sent by the coordination team, by primary health centres, or by general practitioners.

This section concerns the primary screening test results.

- **Columns F, G, H, I: Primary screening test results:** Out of those women screened, how many had:
  - A screen positive result?
  - A screen negative result?
  - An inconclusive/unsatisfactory screen test result?
  - The screen test result is unknown (missing information)?
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

3. Primary screening test results				
Age group (years)	F Nº of women with screen **positive** result	G Nº of women with screen **negative** result	H Nº of women with **inconclusive/unsatisfactory** screen test result	I Nº of women for whom screen result is **unknown**
Stratified by 5 yrs				
20-24				
25-29				
30-34				
35-39				
40-44				
45-49				
50-54				
55-59				
60-64				
65-69				
*Other				
Stratified by 10 yrs				
20-29				
30-39				
40-49				
50-59				
60-69				
*Other				
No age stratification				
All in target age				
Any other information related to screening test results: _____				

This section concerns the further assessment status (colposcopy).

- **Column J, K, L: Further assessment (colposcopy) information:** Out of the women with a positive test result requiring colposcopy:
  - How many had further assessment performed?
  - How many did you know that further assessment was not performed, including those who refused?
  - For how many you don't have information on further assessment status (missing information)?
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

4. Further assessment (colposcopy)			
Age group (years)	J	K	L
	Nº of women with further assessment **performed**	Nº of women with further assessment **not performed**	Nº of women for whom further assessment status is **unknown**
Stratified by 5 yrs			
20-24			
25-29			
30-34			
35-39			
40-44			
45-49			
50-54			
55-59			
60-64			
65-69			
*Other			
Stratified by 10 yrs			
20-29			
30-39			
40-49			
50-59			
60-69			
*Other			
No age stratification			
All in target age			
Any other information related to further assessment: _____			

Further assessment: Additional diagnostic techniques (either immediately after screening or postponed in a referral setting) performed to confirm the nature of a perceived abnormality detected at the screening examination. Example: for cervical cancer it means performing a colposcopy.

This section concerns the final diagnosis.

- **Column M, N, O, P, Q, R, S: Outcomes of final diagnosis**: Out of those women with further assessment performed:
  - How many was detected to have no lesion/benign diagnosis/low grade lesions?
  - How many was detected to have histopathology confirmed high grade lesions of CIN2?
  - How many was detected to have histopathology confirmed high grade lesions of CIN3 and AIS (adenocarcinoma *in situ*)?
  - If you only have aggregated information for histopathology confirmed high grade lesions (CIN2/CIN3/H-SIL/AIS), please fill the **P** column **and** make a note in the "Any other information" box below.
  - If you only have aggregated information for histopathology confirmed precancer lesions not otherwise specified (includes all CIN/SIL/AIS agregated), please fill the **Q** column **and** make a note in the "Any other information" box below.
  - How many was detected to have histopathology confirmed invasive cancer?
  - For how many you don't have information on final diagnosis outcome (missing information)?
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

5. Final diagnosis							
Age group (years)	M	N	O	P	Q	R	S
	Nº of women with final diagnosis **no lesion/ benign/ low grade lesions**	Nº of women with histopathology confirmed **CIN2**	Nº of women with histopathology confirmed **CIN3 and AIS**	Nº of women with histopathology confirmed CIN2 and CIN3 (or H-SIL) and AIS (if only aggregated data is available)	Nº of women with histopathology confirmed precancer "NOS" (**Not Otherwise Specified**) – (if only aggregated data is available)	Nº of women with histopathology confirmed **invasive cancer**	Nº of women with final diagnosis **unknown**
Stratified by 5 yrs							
20-24							
25-29							
30-34							
35-39							
40-44							
45-49							
50-54							
55-59							
60-64							
65-69							
*Other							
Stratified by 10 yrs							
20-29							
30-39							
40-49							
50-59							
60-69							
*Other							
No age stratification							
All in target age							
Any other information related to final diagnosis:							

This section concerns the cancer staging information (for invasive cancer).

- **Column T, U, V, W, X: Cancer staging outcomes**: Provide the distribution of staging as follows, which should be based on the FIGO system:
  - Stage I
  - Stage II
  - Stage III
  - Stage IV
  - Staging not done/unknown
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

6. Cancer staging					
Age group (years)	T	U	V	W	X
	Stage I	Stage II	Stage III	Stage IV	Staging **not done/unknown**
Stratified by 5 yrs					
20-24					
25-29					
30-34					
35-39					
40-44					
45-49					
50-54					
55-59					
60-64					
65-69					
*Other					
Stratified by 10 yrs					
20-29					
30-39					
40-49					
50-59					
60-69					
*Other					
No age stratification					
All in target age					
Any other information related to cancer staging: _____					

This section concerns the treatment information.

- **Column Y, Z, α : Treatment status**: Out of the women with diagnosis of CIN2/CIN3/AIS/invasive cancer, how many:
  - How many initiated treatment?
  - How many did not initiated treatment?
  - For how many you don't have information on treatment status (missing information)?
- ***** For all the data outside the indicated age group or without age information, please fill in the "Other" row **and** add description in the *"Any other information"* box.

7. Treatment			
Age group (years)	Y	Z	α
	Nº of women **initiated** treatment	Nº of women **not initiated** treatment	Nº of women for whom treatment status **unknown**
Stratified by 5 yrs			
20-24			
25-29			
30-34			
35-39			
40-44			
45-49			
50-54			
55-59			
60-64			
65-69			
*Other			
Stratified by 10 yrs			
20-29			
30-39			
40-49			
50-59			
60-69			
*Other			
No age stratification			
All in target age			
Any other information related to treatment: _____			